Melanoma: The intersection of molecular targeted therapy and immune checkpoint inhibition

Current Opinion in Immunology

Volumn 39, Issue , 2016, Pages 30-38

  Lau, Peter Kar Han ^a   Ascierto, Paolo A ^b   McArthur, Grant ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; BINIMETINIB; COBIMETINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; ENCORAFENIB; GAMMA INTERFERON; GLYCOPROTEIN GP 100; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; IPILIMUMAB; MELAN A; MONOPHENOL MONOOXYGENASE; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRAMETINIB; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VEMURAFENIB; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; MELANOMA; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; SKIN NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; SKIN NEOPLASMS;

EID: 84952889071     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.12.006     Document Type: Review

References (54)

1. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
4. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
5. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C.U., Miller W.H., Kaempgen E., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
6. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
7. Larkin J., Ascierto P.A., Dreno B., Atkinson V., Liszkay G., Maio M., Mandala M., Demidov L., Stroyakovskiy D., Thomas L., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014, 371:1867-1876.
8. Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T., Hauschild A., Grob J.J., et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015, 386:444-451.
9. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
10. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
11. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
12. Yoon S., Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Fact 2006, 24:21-44.
13. Greaves W.O., Verma S., Patel K.P., Davies M.A., Barkoh B.A., Galbincea J.M., Yao H., Lazar A.J., Aldape K.D., Medeiros L.J., et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 2013, 15:220-226.
14. Long G.V., Menzies A.M., Nagrial A.M., Haydu L.E., Hamilton A.L., Mann G.J., Hughes T.M., Thompson J.F., Scolyer R.A., Kefford R.F. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29:1239-1246.
15. Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell 2015, 161:1681-1696.
16. Sheppard K.E., McArthur GA: The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res 2013, 19:5320-5328.
17. Vinay D.S., Ryan E.P., Pawelec G., Talib W.H., Stagg J., Elkord E., Lichtor T., Decker W.K., Whelan R.L., Kumara H.M.C.S., et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015.
18. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
19. Chen L., Flies DB: Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013, 13:227-242.
20. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
21. Okazaki T., Honjo T: PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007, 19:813-824.
22. Topalian S.L., Drake C.G., Pardoll DM: Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012, 24:207-212.
23. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
24. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
25. 18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 2012, 30:1628-1634.
26. McArthur G.A., Chapman P.B., Robert C., Larkin J., Haanen J.B., Dummer R., Ribas A., Hogg D., Hamid O., Ascierto P.A., et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15:323-332.
27. Rizos H., Menzies A.M., Pupo G.M., Carlino M.S., Fung C., Hyman J., Haydu L.E., Mijatov B., Becker T.M., Boyd S.C., et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 2014, 20:1965-1977.
28. Shi H., Hong A., Kong X., Koya R.C., Song C., Moriceau G., Hugo W., Yu C.C., Ng C., Chodon T., et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov 2014, 4:69-79.
29. Shi H., Hugo W., Kong X., Hong A., Koya R.C., Moriceau G., Chodon T., Guo R., Johnson D.B., Dahlman K.B., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014, 4:80-93.
30. Van Allen E.M., Wagle N., Sucker A., Treacy D.J., Johannessen C.M., Goetz E.M., Place C.S., Taylor-Weiner A., Whittaker S., Kryukov G.V., et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014, 4:94-109.
31. Hugo W., Shi H., Sun L., Piva M., Song C., Kong X., Moriceau G., Hong A., Dahlman K.B., Johnson D.B., et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 2015, 162:1271-1285.
32. McArthur G.A., Larkin J., Dréno B., Ascierto P.A., Liszkay G., Maio M., Mandalà M., Demidov L., Stroyakovskiy D., Thomas L., et al. Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI)+vemurafenib (VEM) in the phase 3 coBRIM study. European Cancer Congress 2015, vol. 51:S720-S723. European Journal of Cancer, Vienna.
33. Robert C., Karaszewska B., Schachter J., Rutkowski P., Mackiewicz A., Stroyakovskiy D., Lichinitser M., Dummer R., Grange F., Mortier L., et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. European Cancer Congress 2015 2015, vol. 51:S720-S723. European Journal of Cancer, Vienna.
34. Oberholzer P.A., Kee D., Dziunycz P., Sucker A., Kamsukom N., Jones R., Roden C., Chalk C.J., Ardlie K., Palescandolo E., et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012, 30:316-321.
35. Boni A., Cogdill A.P., Dang P., Udayakumar D., Njauw C.N., Sloss C.M., Ferrone C.R., Flaherty K.T., Lawrence D.P., Fisher D.E., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70:5213-5219.
36. Frederick D.T., Piris A., Cogdill A.P., Cooper Z.A., Lezcano C., Ferrone C.R., Mitra D., Boni A., Newton L.P., Liu C., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013, 19:1225-1231.
37. Wilmott J.S., Long G.V., Howle J.R., Haydu L.E., Sharma R.N., Thompson J.F., Kefford R.F., Hersey P., Scolyer RA: Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012, 18:1386-1394.
38. Ferrari de Andrade L., Ngiow S.F., Stannard K., Rusakiewicz S., Kalimutho M., Khanna K.K., Tey S.K., Takeda K., Zitvogel L., Martinet L., et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res 2014, 74:7298-7308.
39. Sumimoto H., Imabayashi F., Iwata T., Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006, 203:1651-1656.
40. Ott P.A., Henry T., Baranda S.J., Frleta D., Manches O., Bogunovic D., Bhardwaj N. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother 2013, 62:811-822.
41. Schadendorf D., Hodi F.S., Robert C., Weber J.S., Margolin K., Hamid O., Patt D., Chen T.T., Berman D.M., Wolchok J.D. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015, 33:1889-1894.
42. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 373:23-34.
43. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015, 372:2521-2532.
44. Daud A., Ribas A., Robert C., Hodi F.S., Wolchok J.D., Joshua A.M., Hwu W.-J., Weber J.S., Gangadhar T.C., Joseph R.W., et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. ASCO Meeting Abstracts, vol. 33 2015, 9005.
45. Atkinson V., Ascierto P.A., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J.C., Rutkowski P., McNeil C., et al. Two-year survival and safety update in patients with treatment-naïve advanced melanoma (MEL) receiving nivolumab or dacarbazine in CheckMate 066. Society for Melanoma Research 2015 Congress 2015, vol. 28. Pigment Cell & Melanoma Research, San Francisco.
46. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., Chmielowski B., Spasic M., Henry G., Ciobanu V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
47. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014, 371:2189-2199.
48. Gangadhar T.C., Hamid O., Smith D.C., Bauer T.M., Wasser J.S., Luke J.J., Balmanoukian A.S., Kaufman D.R., Zhao Y., Maleski J., et al. Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. J Immunother Cancer 2015, 3:O7.
49. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J.C., Rutkowski P., McNeil C., Kalinka-Warzocha E., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015, 372:320-330.
50. Weber J.S., D'Angelo S.P., Minor D., Hodi F.S., Gutzmer R., Neyns B., Hoeller C., Khushalani N.I., Miller W.H., Lao C.D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015, 16:375-384.
51. Jiang X., Zhou J., Giobbie-Hurder A., Wargo J., Hodi F.S. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013, 19:598-609.
52. Liu L., Mayes P.A., Eastman S., Shi H., Yadavilli S., Zhang T., Yang J., Seestaller-Wehr L., Zhang S.Y., Hopson C., et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 2015, 21:1639-1651.
53. Ribas A., Butler M., Lutzky J., Lawrence D.P., Robert C., Miller W., Linette G.P., Ascierto P.A., Kuzel T., Algazi A.P., et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. ASCO Meeting Abstracts, vol. 33 2015, 3003.
54. Hamid O., Patel H.N., Hodi F.S., Amaria R.N., Boasberg P., Sullivan R., Wallin J., He X., Cha E., Richie N., et al. Preliminary clinical safety, tolerability and activity of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600 metastatic melanoma. Society for Melanoma Research 2015 Congress 2015, vol. 28:778. Pigment Cell & Melanoma Research, San Francisco.